Items where authors include "Prescilla, R."

Article

Paller, A.S., Silverberg, J.I., Simpson, E.L. et al. (7 more authors) (2025) The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study. Journal of the American Academy of Dermatology, 92 (1). pp. 116-126. ISSN 0190-9622

Cork, M.J. orcid.org/0000-0003-4428-2428, Lockshin, B., Pinter, A. et al. (3 more authors) (2024) Clinically meaningful responses to dupilumab among children aged 6 months to 5 years with moderate-to-severe atopic dermatitis who did not achieve clear or almost clear skin according to the investigator’s global assessment: a post hoc analysis of a phase 3 trial. Acta Dermato-Venereologica, 104. 13467. ISSN 0001-5555

Cork, M.J., Thaçi, D., Eichenfield, L.F. et al. (8 more authors) (2023) Dupilumab safety and efficacy in a phase III open-label extension trial in children 6–11 years of age with severe atopic dermatitis. Dermatology and Therapy, 13. pp. 2697-2719. ISSN 2193-8210

Siegfried, E.C., Simpson, E.L. orcid.org/0000-0001-7353-5979, Cork, M.J. et al. (7 more authors) (2023) Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years. Dermatology and Therapy, 13 (9). pp. 1987-2000. ISSN 2193-8210

Paller, A.S. orcid.org/0000-0001-6187-6549, Siegfried, E.C., Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (8 more authors) (2023) Laboratory safety from a randomized 16-week phase III study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Pediatric Drugs, 25. pp. 67-77. ISSN 1174-5878